These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 14585596)

  • 21. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death.
    Zhang W; Zecca L; Wilson B; Ren HW; Wang YJ; Wang XM; Hong JS
    Front Biosci (Elite Ed); 2013 Jan; 5(1):1-11. PubMed ID: 23276965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.
    Fasano M; Giraudo S; Coha S; Bergamasco B; Lopiano L
    Neurochem Int; 2003 Jun; 42(7):603-6. PubMed ID: 12590943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuromelanin of human substantia nigra: physiological and pathogenic aspects.
    Zucca FA; Giaveri G; Gallorini M; Albertini A; Toscani M; Pezzoli G; Lucius R; Wilms H; Sulzer D; Ito S; Wakamatsu K; Zecca L
    Pigment Cell Res; 2004 Dec; 17(6):610-7. PubMed ID: 15541018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
    Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
    Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
    Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normative data of dopaminergic neurotransmission functions in substantia nigra measured with MRI and PET: Neuromelanin, dopamine synthesis, dopamine transporters, and dopamine D
    Ito H; Kawaguchi H; Kodaka F; Takuwa H; Ikoma Y; Shimada H; Kimura Y; Seki C; Kubo H; Ishii S; Takano H; Suhara T
    Neuroimage; 2017 Sep; 158():12-17. PubMed ID: 28655632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of neuromelanin on oxidative pathways within the human substantia nigra.
    Double KL; Ben-Shachar D; Youdim MB; Zecca L; Riederer P; Gerlach M
    Neurotoxicol Teratol; 2002; 24(5):621-8. PubMed ID: 12200193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R
    Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
    Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
    J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neuromelanin in neurons of substantia nigra lacking tyrosine hydroxylase].
    Grigor'ev IP; Sukhorukova EG; Kolos EA; Korzhevskiĭ DE
    Morfologiia; 2012; 141(2):65-7. PubMed ID: 22913142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy.
    Enochs WS; Nilges MJ; Swartz HM
    J Neurochem; 1993 Jul; 61(1):68-79. PubMed ID: 8390568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for specific phases in the development of human neuromelanin.
    Fedorow H; Halliday GM; Rickert CH; Gerlach M; Riederer P; Double KL
    Neurobiol Aging; 2006 Mar; 27(3):506-12. PubMed ID: 15916835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra.
    Aime S; Fasano M; Bergamasco B; Lopiano L; Valente G
    J Neurochem; 1994 Jan; 62(1):369-71. PubMed ID: 8263538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.
    Carballo-Carbajal I; Laguna A; Romero-Giménez J; Cuadros T; Bové J; Martinez-Vicente M; Parent A; Gonzalez-Sepulveda M; Peñuelas N; Torra A; Rodríguez-Galván B; Ballabio A; Hasegawa T; Bortolozzi A; Gelpi E; Vila M
    Nat Commun; 2019 Mar; 10(1):973. PubMed ID: 30846695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.
    Xing Y; Sapuan A; Dineen RA; Auer DP
    Mov Disord; 2018 Nov; 33(11):1792-1799. PubMed ID: 30423212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.